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Abstract
Background: The putative tumor metastasis suppressor 1(MTSS1) is an actin-binding scaffold protein that has been
implicated to play an important role in carcinogenesis and cancer metastasis, yet its role in the development of
gastric cancer has not been well illustrated. In this study, we detected MTSS1 expression and explored its clinical
significance in gastric cancer.
Methods: Immunohistochemistry was performed using tissue microarrays containing gastric adenocarcinoma
specimens from 1,072 Chinese patients with normal adjacent mucosa, primary gastric cancer and lymph node (LN)
metastasis and specific antibody against MTSS1. MTSS1 mRNA and protein expression were detected by reverse
transcription-polymerase chain reaction and Western blotting. The clinical follow-up was done in the 669 patients
living in Shanghai that was chose from the 1072 cases.
Results: Complete loss of MTSS1 expression was observed in 751 cases (70.1%) of the 1,072 primary tumors and
103 (88%) of 117 nodal metastases; and loss of MTSS1 expression was significantly associated with poorly
differentiated tumors, large tumor size, deep invasion level, the presence of nodal metastases and advanced
disease stage. Moreover, multivariate analysis demonstrated that loss of MTSS1 expression correlated significantly
with poor survival rates (RR = 0.194, 95% CI = 0.144-0.261, P < 0.001).
Conclusions: MTSS1 expression decreased significantly as gastric cancer progressed and metastasized, suggesting
MTSS1 may serve as a useful biomarker for the prediction of outcome of gastric cancer.
Background
Gastric carcinoma (GC), which is the second most com-
mon cause of cancer-related death in the world, deprives
more than 700,000 lives per annum [1]. Its incidence
varies considerably worldwide and has recently been
decreasing in developed countries, but remains stably in
developing countries [2-4]. Furthermore, the fact that
gastric cancer is insensitive to conventional chemother-
apy and is rarely amenable to radiotherapy leaves the
survival durations in patients with gastric cancer
unchanged in recent years. This highlights the need for
the determination of prognostic factors predicting the
outcome and the development of novel therapeutic stra-
tegies. Previous studies have indicated that disease stage
and lymph node metastasis are the most important
prognostic factors in gastric cancer. Moreover, some
molecular markers have been identified and attempted
to use clinically [5-7]. Nevertheless, other potential
prognostic factors related to survival in these patients
remain unclear.
Metastasis suppressor 1 (MTSS1), also known as MIM
(missing in metastasis), was originally identified by Lee
et al [8] as a potential metastasis suppressor gene that
was present in non-metastatic bladder cancer cell lines,
but was not expressed in a metastatic bladder cancer
cell line. This gene, mapped to human chromosome
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dicted to be an actin-binding protein of 356 amino acids
with homology to the WASp (Wiscott-Aldrich Syn-
d r o m ep r o t e i n )f a m i l y[ 8 ] .F u n c t i o n a la n a l y s e so f
MTSS1 have shown that MTSS1 induced actin-rich pro-
trusions resembling microspikes and lamellipodia at the
plasma membrane and promoted disassembly of actin
stress fibres [9]. Actin filament assembly is associated
with cytoskeletal structure organization and many forms
of cell motility [10]. These data have suggested that
MTSS1 protein may be important in regulating cytoske-
letal dynamics, and as a consequence it would play a
potential role in the invasion and metastatic behaviour
of cancer cells.
The study surrounding MTSS1 is quite small, yet this
protein has been the subject of controversy. Preliminary
analysis by Northern blotting demonstrated that MTSS1
is widely expressed but is most abundant in spleen, thy-
mus, testis, and prostate, with low levels also detected in
uterus and colon [8]. Since this pioneering article, other
reports have indicated that MTSS1 played a role as a
metastasis suppressor in prostate cancer [11,12], bladder
cancer [8,11,13] and benign lesions, but up-regulated in
basal cell carcinomas [14]. However, other evidences
showed that MTSS1 is unlikely to be a metastasis sup-
pressor. It acts as a scaffold protein that interacts with
actin-associated proteins to modulate lamellipodia for-
mation [15]. Ma et al suggests that MTSS1 is a regula-
tor of carcinogenesis in hepatocellular carcinoma [16].
And it is a member of the sonic hedgehog (SHH) signal-
ling pathway that modulates Gli responses during
growth and carcinogenesis [14].
Although these studies cited above suggested MTSS1
as a promising candidate biomarker and playing an
important role in tumorigenesis, little is known about
the function of MTSS1 in gastric cancer. In our study,
we sought to determine the expression of MTSS1 in
resected gastric cancers and investigate the correlation
of MTSS1 expression and clinicopathologic features and
survival, in an attempt to discover the potential influ-
ence of MTSS1 on the development of gastric cancer.
Methods
Patient specimens
A total of 1,072 patients with gastric cancer who under-
went curative surgery at Changhai Hospital in Shanghai,
People’s Republic of China, from 2001 to 2005 were
enrolled in this study. Mean age of these patients was
59 years old; 757(71%) were male and 315 (29%) were
female. All the other clinicopathological characteristics
of these patients could be found in previous study [17].
Clinical follow-up results were available for the 669
patients from the Shanghai area (mean follow-up dura-
tion, 40 months [range, 1-110 months]). Total number
of death event was 380 cases, and 289 cases are still
alive. All of the tissue specimens were obtained for the
present study with patient informed consent, and the
use of the human specimens was approved by the Chan-
ghai Hospital Institutional Review Board.
Immunohistochemistry and evaluation of immunostaining
Tissue sections were deparaffinized in xylene, and then
rehydrated in graded concentrations of ethyl alcohol
(100%, 95%, 75%, then water). TMA sections were
microwave-treated twice in citrate buffer (PH 6.0) at 99°
C for 6 min. The sections were placed in 3% H2O2 for
10 min to inhibit the endogenous peroxide activity,
washed three times with phosphate-buffered saline
(PBS) buffer for 5 min and placed in normal goat serum
as blocking antibody at room temperature for 10 min.
The primary antibodies used were ab56780 (Abnova,
Caltag-Medsystems Ltd., Buckingham, UK, 1:50) for
MTSS1. After incubation at 4°C for 24 h, sections were
washed three times with PBS buffer for 10 min. Biotiny-
lated anti-mouse/rabbit immunoglobulin was used as
the second antibody. 3, 3-Diaminobenzidine (DAB) was
used as a chromogen. The sections were counter-stained
with hematoxylin.
All slices were evaluated without knowledge of the
clinical outcome. MTSS1 protein expression in the
1,072 cases was evaluated by two individuals (G. Y. and
Y. C.) under an Olympus CX31 microscope (Olympus,
Center Valley, PA). Sections were considered positive
for MTSS1 when more than 5% of tumor cells were
stained in the cell cytoplasm. Staining was scored inde-
pendently by the two individuals who were blinded to
each other’s findings.
RNA preparation and reverse transcription- polymerase
chain reaction
Total cellular RNA was isolat e df r o mt h eh o m o g e n i s e d
gastric samples using the AB gene Total RNA Isolation
Reagent (Advanced Biotechnologies Ltd., Epsom, Surrey,
UK). RNA concentration and quality were determined
through spectrophotometric measurement (WPA UV
1101, Biotech Photometer, Cambridge, UK). cDNA was
generated from 1 ug of each RNA sample and a reverse
transcribed using a transcription kit (Takara, Kyoto,
Japan). The quality of DNA was verified using b-actin
primers (sense:GCTGTCACCTTCACCGTTC; antisense:
CCATCGTCCACCGCAAAT). MTSS1 mRNA levels
were assessed using MTSS1 primers: (sense: TGG
GTCCACTGAGCCCCACACATTGTTG and antisense:
GGTGGCCATTGTGGG GTGGAATG -AA). PCR
amplification was carried out with Ex Taq DNA poly-
merase reaction system (Takara, Kyoto, Japan). Condi-
tions for PCR were 94°C 4 min,30 s at 94°C for
denaturation, 30 s at 60°C for annealing and 90 s at 72°
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phoresed through 1.5% agarose gels and analyzed by
computerized densitometric scanning of the images
using the Quantity-One imaging software normalized
with internal b-actin control.
Western Blotting Assay
Whole-cell lysates were prepared from human gastric
cancer and normal gastric tissue specimens. Standard
Western blotting was performed using a mouse mono-
clonal antibody against human MTSS1 in a 1:50 dilution
(Abnova, Caltag-Medsystems Ltd., Buckingham, UK)
and an anti-mouse/rabbit immunoglobulin (ZB-2305,
Jackson, America). Equal protein sample loading was
monitored by probing the same membrane filter with an
anti-b-actin antibody. The probe proteins were detected
using the Amersham enhanced chemiluminescence sys-
tem according to the manufacturer’s instructions.
Statistical analysis
Association among factors was evaluated by the Pearson
c2 test. Within-group correlations of continuous and
ordinal variables were assessed using Pearson’sc o r r e l a -
tion coefficient or Spearman’s rank correlation coeffi-
cient when appropriate. Differences between samples
mRNA and Western Blotting were assessed by paired
t-test. Survival curves were calculated according to the
Kaplan-Meier method. Survival data shown in this study
were pertaining to overall survival. To this end, non-
gastric cancer deaths were considered as lost to follow
up as of time of death in the statistical analysis. Differ-
ences between survival curves were examined with the
log-rank test. Multivariate analysis of prognostic factors
related to overall survival was carried out using Cox’s
proportional hazards model and a stepwise procedure.
The covariates included sex, age, histological classifica-
tion, Lauren’s classification, tumor size, location of
tumor, depth of invasion, lymph node metastasis, and
disease stage. The accepted level of significance was P <
0.05. Statistical analyses and graphics were performed
with the SPSS 13.0 statistical package (SPSS, Inc.,
Chicago, IL).
Results
MTSS1 expression in patients with gastric cancer
All tissue microarray block sections selected for this
study contained both normal and malignant epithelium.
Figure 1 shows examples of tissue immunostained for
the protein evaluated. MTSS1 immunostaining was of
cytoplasm localization. The epithelium in normal
mucosa specimens showed visible MTSS1 staining (Fig-
ure 1A). 751 cases (70.1%) showed negative staining of
MTSS1 and the other 321 cases showed positive stain-
ing. These results were in concordance with that in the
Western blotting study (Figure 1G). Importantly, we
detected high expression of MTSS1 in adjacent normal
epithelium but drastically reduced MTSS1 expression in
the tumor cells (Figure 1F). Moreover, we observed that
expression of MTSS1 varied with the different histologi-
cal types. From the well and moderate histological levels
to the histological undifferentiated, the expression of
MTSS1 was gradually decreased (Figure 1B-D). In addi-
tion, MTSS1 expression was down-regulated in the liver
metastases compared with the adjacent normal liver tis-
sues, which serves as a positive control (Figure 1E).
Reverse transcription RT-PCR was used to evaluate
MTSS1 expression level in 30 normal adjacent mucosa
and 30 paired primary gastric cancer tissues. The result
verified that MTSS1 expression level in GC tissues was
significantly different from the paired normal adjacent
mucosa. Consistent with the microarray data, this analy-
sis showed that the MTSS1 expression mRNA level in
GC was significantly lower than in normal adjacent
mucosa. (P < 0.001) (Figure 1H).
Correlation between MTSS1 expression and
clinicopathologic characteristics of gastric cancer
The GC patients were divided into two groups accord-
ing to the MTSS1 expression levels:
MTSS1 low or negative expressers (n = 751) and
MTSS1 positive expressers (n = 321). Correlation
between MTSS1 expression level and clinicopathologic
characteristics of GC is summarized in Table 1. A sta-
tistically significant association was observed between
MTSS1 expression level and tumor size, histology and
Lauren’s classification. In 634 cases well-differentiated
to moderately differentiated tumors, 235 (37.1%) of
the cases had positive MTSS1 expression in GC tissue;
whereas in 438 poorly differentiated tumors, only 86
(19.6%) presented positive MTSS1 expression (P <
0.001). And in 618 cases of intestinal type in Lauren’s
classification, 211 (34.1%) presented positive MTSS1
expression but 110 (24.2%) cases with the diffuse-type
showed positive. In the 825 cases of GC with tumor
size (<6 cm), 265 (32.1%) presented MTSS1 expres-
sion, while only 56 (22.7%) of 247 cases of GC with
tumor size (≥6 cm) presented MTSS1 expression (P =
0.005).
We also observed that loss of MTSS1 expression cor-
related with advanced T, N, and TNM stage. Loss of
MTSS1 expression occurred more frequently in large
gastric tumors (invasion to level T3-T4) (76.1%) than in
small ones (level T0-T2) (55.4%; P < 0.001) and more
frequently in gastric tumors with regional LN metastasis
(76.3%) than in N0-stage tumors (57.6%; P < 0.001).
With regard to TNM stage, loss of MTSS1 expression
was significantly associated with advanced disease stage:
78.8% at stage III -IV and 57% at stage I- II (P < 0.001).
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Page 3 of 9Figure 1 Analysis of MTSS1 expression in human gastric cancers and adjacent normal mucosa specimens. A: Normal (nonneoplastic)
gastric mucosa; B and C: Gastric cancer positive expression of MTSS1 in well-(B) and moderate-(C) differentiated tumors. D: Gastric cancer
negative MTSS1 expression; E: MTSS1 expression in the hepatic metastasis and adjacent nonneoplastic liver tissues; F: MTSS1 expression in gastric
cancer and adjacent nonneoplastic mucosa tissues; G and H: Western blotting analysis (G) and RT-PCR analysis (H) of MTSS1 in GC tissues and
surrounding nontumor tissues, b-actin as a parallel control, N: surrounding nontumor tissues; T: tumor tissues.
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gastric tumors and LN metastases
In the tissue microarrays, 117 cases had available
matched LN metastases. The MTSS1 expression rate in
the metastases (12%) was lower than that in the primary
tumors (26.5%) (P = 0.005).
Relationship of loss of MTSS1 expression with poor
outcome in patients with gastric cancer
Figure 2 presents several survival curves of the 669 GC
patients, with the median cumulative survival duration in
patients with resected gastric carcinoma of 40 months.
Kaplan-Meier survival analyses revealed that the GC
patients with loss MTSS1 expression had a significantly
poor prognosis compared to those with positive MTSS1
expression (18 months versus 76 months; P < 0.001, Fig-
ure 2A). Furthermore, subgroup analysis of MTSS1
according to TNM was performed (Figure 3A-D). The
outcomes of patients with MTSS1-negative expression
were worse in each stage than that with MTSS1-positive
expression (> 82 months for MTSS1-positive tumors vs 72
months for MTSS1-negative tumors in stage I, P < 0.001;
>78 months vs 32 months in stage II, P < 0.001; >70
months vs 18 months in stage III, P < 0.001; >57 months
vs 11 months in stage IV, P < 0.001). Aside from MTSS1
expression, survival analysis of other clinicopathological
factors also revealed that lymph node metastases and clini-
cal TNM stage were associated with prognosis of the
patients with gastric cancer (Figure 2B.C).
Multivariate analysis using the Cox proportional
hazards model for all of the significant variables in the
univariate analysis showed that age, differentiation,
nodal invasion, TNM stage and MTSS1 expression were
independent prognostic factors (Table 2).
Discussion
Although metastasis suppressor 1 (MTSS1) may be a
critical regulator of carcinogenesis in different cancers,
study of MTSS1 has been mainly restricted to several
cancers and available data seem to be controversial,
leaving the involvement of MTSS1 in cancer not clearly
defined. Given that gastric cancer is one of the most
malignant cancers in the world and that tumor recur-
rence and metastases are the major causes of death in
patients with gastric cancer, resulting in a poor prog-
nosis of the disease, we set out to investigate the role of
MTSS1 in gastric cancer. In this study, we found that
loss of MTSS1 expression was significantly associated
with important clinical determinants of prognosis for
gastric cancer including poorly differentiated tumors,
Table 1 Summary of clinicopathological parameters of gastric cancer and their correlation with loss of MTSS1 protein
expression
Features No. of patients (%) Loss of MTSS1 expression (%) P value
Tumor size 0.005
<6 cm 825(77.0%) 560(67.9%)
≥6 cm 247(23.0%) 191(77.3%)
Site NS
Cardia and fundus 180(16.8%) 127(70.6%)
Corpus 329(30.7%) 229(69.6%)
Antrum 519(48.4%) 359(69.2%)
Whole 44(4.1%) 36(81.8%)
pT stage < 0.001
T0-T2 312(29.1%) 173(55.4%)
T3/T4 760(70.9%) 578(76.1%)
pN stage < 0.001
N0 356(33.2%) 205(57.6%)
N1-3 716(66.8%) 546(76.3%)
Disease stage < 0.001
I/II 427(39.8%) 243(57%)
III/IV 645(60.2%) 508(78.8%)
Differentiation < 0.001
Well/Moderate 634(59.1%) 399(62.9%)
Poorly 438(40.9%) 352(80.4%)
Lauren’s classification < 0.001
Intestinal-type 618(57.6%) 407(65.9%)
Diffuse-type 454(42.4%) 344(75.8%)
Total 1072 751(70.1%)
Liu et al. BMC Cancer 2010, 10:428
http://www.biomedcentral.com/1471-2407/10/428
Page 5 of 9diffuse-type in Lauren’s classification, large tumor size,
deep invasion level, the presence of nodal metastases
and advanced disease stage. And patients without
MTSS1 expression had shorter median survival dura-
tions than that with MTSS1 expression. Moreover, our
immunohistochemistry data clearly revealed that MTSS1
expression significantly decreased from normal tissues
to primary tumors to nodal metastases. To the best of
our knowledge, this is the first clinical evidence that
MTSS1 might play an important role in gastric cancer
progression and metastasis.
Accumulating evidences suggested that poorly differ-
entiated tumors have higher growth and recurrence
rates than well-differentiated tumors do [17]. Previous
study reported that down-regulation of MTSS1 expres-
sion might correlate with the transition of tumor cells
from distinct epithelium-like morphology to less differ-
entiated carcinomas [18]. Consistently, in our study,
MTSS1 protein expression was lost more frequently in
poorly differentiated tumors than in well-differentiated
tumors, suggesting that MTSS1 is a differentiation mar-
ker for gastric cancer. However, another report reveals
that an incremental increase in MTSS1 expression was
detected from healthy normal liver donors to non tumor
tissue specimens and then to their matched hepatocellu-
lar carcinoma tumor tissue specimens. Specifically, a
Figure 2 Kaplan-Meier curves of survival durations in patients with gastric cancer treated with primary gastrectomy. (A) Patients with
cancers negative for MTSS1 expression had shorter survival durations than did patients with MTSS1 expression in their gastric cancers (P <
0.001). (B) The survival durations were significantly worse in patients with higher N stages than in those with lower N stages (P < 0.001). (C) The
survival durations were significantly worse in patients with advanced stages than in those with early stages (P < 0.001).
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early stages of the disease, suggesting that MTSS1 may
play an important role in promoting the early develop-
ment of hepatocellular carcinoma [16]. Inasmuch as the
role of MTSS1 has not been clearly defined to date
because of contradicting published data, we speculate
that the role of MTSS1 could be cancer or tissue type
specific.
Risk factors for gastric cancers have been explored in
a number of studies, including status of lymph nodes,
depth of tumor invasion, age at diagnosis, TNM stage
and some molecular markers [5,7,19-23]. In the present
study, we confirmed that age, histology, nodal metastasis
and TNM stage were independent predictors for gastric
cancer. Furthermore, MTSS1 expression was found to
be significantly correlated with prognosis in univariate
survival analysis and it still kept its prognostic value in
multivariate survival analysis. Positive associations
between MTSS1 expression and other clinicopathologic
features, such as tumor size, depth of tumor invasion,
status of lymph nodes, TNM stage, differentiation and
Lauren’s classification were indicated. All these findings
suggested that MTSS1 expression alone was a potential
molecular marker for predicting outcome in patients
who undergo gastrectomy for gastric cancer.
Metastasis is a fatal step in the progression of gastric
cancer and has become one of the most challenging
problems in tumor therapy [24]. The spread of tumor
cells is a complicated and multistage process and
requires altered expression of many different genes [25].
Nixdorf et al [ 1 3 ]i n d i c a t e dt h a td o w n - r e g u l a t i o no f
MTSS1 occurred in BL17/2 bladder tumor cell lines
with invasive abilities. Expression of MTSS1 has also
been shown to be reduced in prostate cancer and can
contribute to tumor growth and development, as well as
metastasis [12]. In this study, we observed significantly
lower expression of MTSS1 in the nodal metastases of
Figure 3 Subgroup analysis of MTSS1 according to TNM. (A-D) Stage-specific survival curves showed patients with loss of MTSS1 expression
had poor survival to those with positive MTSS1 expression in each stage (P < 0.001).
Table 2 Cox proportional hazards model analysis of
prognostic factors
B SE Wald RR 95% CI P
value
Age 0.416 0.109 14.652 1.516 1.225 1.876 <.001
Tumor size 0.107 0.119 0.800 1.112 0.881 1.405 0.371
Differentiation 0.202 0.091 4.883 1.224 1.023 1.464 0.027
Location 0.028 0.068 0.172 1.029 0.900 1.176 0.678
Nodal metastasis 0.288 0.093 9.588 1.334 1.112 1.601 0.002
Gastric wall
invasion
0.267 0.144 3.409 1.305 0.984 1.732 0.065
TNM 0.341 0.144 5.643 1.406 1.061 1.863 0.018
MTSS1 -1.640 0.152 116.494 0.194 0.144 0.261 <.001
SE, standard error
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frequency of down regulation of MTSS1 expression in
primary gastric tumors and lost MTSS1 expression in
metastases and their direct association with poor out-
come of gastric cancer indicated that MTSS1 could sup-
press tumor invasion and metastasis, and might be a
candidate prognostic factor for lymph node metastasis
and tumor progression. This notion is clearly supported
by a recent study showing that biological overexpression
of MTSS1 significantly suppressed the invasive, migra-
tory, growth and adherence properties of a human
breast cancer cell line [26]. However, Bompard et al
[15] found that MTSS1 expression is not dependent on
the metastatic state of the cells. We also observed
MTSS1 expression in six nodal metastases but not in
matched primary tumors. This discrepancy makes us
presume that there is a possibility that the components
which regulate MTSS1 may create specific interactions
with different microenvironments between primary
regions and target organs. Expression of MTSS1 is
regulated by an epigenetic event that is differently repre-
sented in different sites. The mechanism for the down-
regulation of MTSS1 to tumor progression, especially
metastasis, is not clear. It was reported that its expres-
sion is regulated by DNA methylation, a potential hall-
m a r ko fag e n el i k e l yt ob ei n v o l v e di nt u m o ri n i t i a t i o n
and progression [11]. Additionally, several studies indi-
cated that MTSS1 may be due to actin binding, reorga-
nisation or changes in cell adhesion or tyrosine
phosphorylation upon loss of MTSS1 [27]. As reorgani-
zation of the actin cytoskeleton has been extensively stu-
died in cancer and is the primary mechanism of cell
motility and migration, which are critical steps, involved
in tumor carcinogenesis [28]. Further functional investi-
gations are worthwhile to explore the precise mechan-
ism of the carcinogenic effect of MTSS1 with the goal
of developing potential therapies targeting MTSS1 as an
indicator for gastric cancer.
Conclusion
To the best of our knowledge, this is the first report
demonstrating the clinicopathological significance of
MTSS1 expression in gastric cancer. Our results showed
that loss of MTSS1 expression was associated with large
tumor size, low differentiation, deep invasion level,
advanced tumor stage, the presence of nodal metastasis,
and poor outcome in patients who underwent gastrect-
omy. MTSS1 expression may serve as a useful biomar-
ker for the prediction of outcome of gastric cancer.
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